Trials / Completed
CompletedNCT01225237
A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients
Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 296 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Male
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
A study to verify the superiority of ramosetron hydrochloride (Irribow Tablets) to placebo for male patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramosetron | oral |
| DRUG | Placebo | oral |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2010-10-20
- Last updated
- 2014-10-15
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01225237. Inclusion in this directory is not an endorsement.